IceCure Medical's Landmark Recognition in Breast Cancer Treatment
IceCure Medical Ltd. is celebrating a significant moment in breast cancer treatment as the American Society of Breast Surgeons (ASBrS) proposes guidelines that include cryoablation for low-risk breast cancer patients. The upcoming guidelines signify a possible revolution in how breast cancer is addressed, particularly for patients with less severe forms of the disease.
The Impact of Updated Guidelines on Cryoablation
The ASBrS is in the final phases of updating its "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast." The inclusion of cryoablation in these guidelines is poised to enhance its acceptance among breast surgeons, fostering a new era of minimally invasive surgery for suitable candidates.
As the guidelines near completion, they reflect ongoing advancements in cryoablation technology and the increasing endorsement from medical professionals. The addition of this treatment option is not only a significant progression for IceCure Medical but also represents a shift towards more patient-centered care approaches.
Clinical Evidence Supporting Cryoablation
A notable clinical study, IceCure's ICE3 trial, laid a firm foundation for this advancement in treatment protocols. This study is distinguished as the largest of its kind in the United States and has demonstrated that cryoablation, combined with endocrine therapy, shows local recurrence rates of only 3.1% over five years for patients with hormone receptor-positive and HER2-breast cancer.
The results from the ICE3 trial are promising, as they indicate cryoablation provides similar efficacy and safety to traditional lumpectomy procedures while offering excellent cosmetic outcomes and high patient satisfaction rates. This groundbreaking data has garnered attention and support from various medical professionals advocating for the adoption of cryoablation as a standard treatment.
Industry Professional Insights
Eyal Shamir, CEO of IceCure, expressed his optimism about the ASBrS's decision, stating, "The proposed update to the ASBrS treatment guidelines represents an important step forward for breast cancer care. We are excited to see cryoablation being recognized as a viable option for low-risk patients. The speed of the recognition by ASBrS after the recent FDA clearance is remarkable. We anticipate this will encourage other medical societies to follow suit, broadening the acceptance of cryoablation in clinical practices."
Commercial Growth and Adoption of ProSense®
IceCure's ProSense® system, which administers cryoablation, has witnessed an upsurge in interest across North America. Recently, installations have taken place in several prestigious medical institutions, illustrating the increasing demand for effective, minimally invasive treatments. The FDA's marketing authorization has fueled this growth, allowing more healthcare providers access to this innovative technology.
With a target patient population of approximately 200,000 women each year needing breast cryoablation, including those over 70 years old and patients who are not surgical candidates, the pathway is being paved for widespread clinical support and usage.
About IceCure Medical's Innovative Solution
The ProSense® Cryoablation System is the first device to receive FDA marketing approval specifically for local treatment of low-risk breast cancer patients aged 70 and above. It offers a less invasive method to manage tumors through freezing, a relatively quick procedure that requires no surgical intervention. This device is uniquely designed to create significant lethal zones using liquid nitrogen, enhancing its effectiveness in treating various types of lesions.
Through its efficient design, ProSense® accelerates recovery reduces pain and minimizes surgical risks, ultimately enhancing patient and provider experiences. This innovative solution opens the door for more office-based procedures, allowing for quicker patient turnover and satisfactory outcomes.
Frequently Asked Questions
What is cryoablation?
Cryoablation is a minimally invasive technique that destroys tumors by freezing them, providing a non-surgical option for cancer treatment.
What are the benefits of the ProSense® system?
The ProSense® system offers rapid recovery, reduced pain, and lower risks associated with traditional surgery, enhancing the patient experience.
How has the FDA reacted to cryoablation treatments?
The FDA granted marketing authorization for cryoablation technology, recognizing its effectiveness as a treatment for low-risk breast cancer.
What are the implications of the ASBrS guidelines?
The new ASBrS guidelines are expected to prompt more breast surgeons to recommend cryoablation as a treatment option, improving access for patients.
How does IceCure Medical stand out in the market?
IceCure Medical focuses on innovative liquid-nitrogen-based cryoablation systems, providing safe and effective alternatives to surgical tumor removals.
